[go: up one dir, main page]

BRPI0918564A2 - inibidores - Google Patents

inibidores

Info

Publication number
BRPI0918564A2
BRPI0918564A2 BRPI0918564A BRPI0918564A BRPI0918564A2 BR PI0918564 A2 BRPI0918564 A2 BR PI0918564A2 BR PI0918564 A BRPI0918564 A BR PI0918564A BR PI0918564 A BRPI0918564 A BR PI0918564A BR PI0918564 A2 BRPI0918564 A2 BR PI0918564A2
Authority
BR
Brazil
Prior art keywords
inhibitors
Prior art date
Application number
BRPI0918564A
Other languages
English (en)
Inventor
Andreas Treml
Antje Hamann
Hans-Ulrich Demuth
Michael Almstetter
Michael Thormann
Robert Sommer
Torsten Hoffmann
Ulft-Torsten Gaertner
Ulrich Heiser
Original Assignee
Probiodrug Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Probiodrug Ag filed Critical Probiodrug Ag
Publication of BRPI0918564A2 publication Critical patent/BRPI0918564A2/pt
Publication of BRPI0918564B1 publication Critical patent/BRPI0918564B1/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Anesthesiology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Pregnancy & Childbirth (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
BRPI0918564-0A 2008-09-04 2009-09-04 Derivados de imidazolidina como inibidores, seu processo de preparação e seu uso, e composição farmacêutica BRPI0918564B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9411808P 2008-09-04 2008-09-04
US61/094,118 2008-09-04
PCT/EP2009/061453 WO2010026212A1 (en) 2008-09-04 2009-09-04 Novel inhibitors

Publications (2)

Publication Number Publication Date
BRPI0918564A2 true BRPI0918564A2 (pt) 2015-12-01
BRPI0918564B1 BRPI0918564B1 (pt) 2023-11-28

Family

ID=41278686

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0918564-0A BRPI0918564B1 (pt) 2008-09-04 2009-09-04 Derivados de imidazolidina como inibidores, seu processo de preparação e seu uso, e composição farmacêutica

Country Status (17)

Country Link
US (1) US8962860B2 (pt)
EP (1) EP2344157B1 (pt)
JP (1) JP5707327B2 (pt)
KR (1) KR101694556B1 (pt)
CN (1) CN102186475B (pt)
AU (1) AU2009289238B2 (pt)
BR (1) BRPI0918564B1 (pt)
CA (1) CA2735795C (pt)
DK (1) DK2344157T3 (pt)
EA (1) EA021150B1 (pt)
ES (1) ES2599621T3 (pt)
IL (1) IL211018A (pt)
MX (1) MX2011002106A (pt)
NZ (1) NZ591531A (pt)
SG (1) SG193828A1 (pt)
WO (1) WO2010026212A1 (pt)
ZA (1) ZA201100898B (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2344158B1 (en) * 2008-09-04 2017-12-27 Probiodrug AG Use of isoqc inhibitors
NZ598685A (en) 2009-09-11 2013-05-31 Probiodrug Ag Heterocylcic derivatives as inhibitors of glutaminyl cyclase
US20110152341A1 (en) 2009-12-22 2011-06-23 Probiodrug Ag Cleavage of b-amyloid precursor protein
US8530670B2 (en) * 2011-03-16 2013-09-10 Probiodrug Ag Inhibitors
WO2012163773A1 (en) * 2011-05-27 2012-12-06 Probiodrug Ag Radiolabelled glutaminyl cyclase inhibitors
AU2014230249B2 (en) * 2013-03-15 2016-09-01 Vivoryon Therapeutics N.V. Novel inhibitors
JP2018501482A (ja) 2014-12-19 2018-01-18 プロビオドルグ エージー pGlu−Abetaペプチドの検出のための新規の方法
CN108658869A (zh) * 2017-03-29 2018-10-16 复旦大学 具有抗肿瘤活性的化合物及其制备方法和在制药中的用途
GB201705263D0 (en) * 2017-03-31 2017-05-17 Probiodrug Ag Novel inhibitors
RU2662559C1 (ru) * 2017-10-27 2018-07-26 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Новый ингибитор глутаминилциклаз и его применение для лечения заболеваний легких и дыхательных путей
RU2665633C1 (ru) * 2017-05-26 2018-09-03 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Новый ингибитор глутаминилциклаз и его применение
EP3461819B1 (en) 2017-09-29 2020-05-27 Probiodrug AG Inhibitors of glutaminyl cyclase
EP3521308B1 (en) 2018-01-31 2024-03-13 Vivoryon Therapeutics N.V. Humanized and de-immunized antibodies
ES2836885T3 (es) 2018-02-23 2021-06-28 Fraunhofer Ges Forschung Nuevos inhibidores de glutaminil ciclasas bacterianas para su uso en el tratamiento de periodontopatías y enfermedades relacionadas
TWI715156B (zh) 2018-08-31 2021-01-01 財團法人國家衛生研究院 苯并咪唑化合物及其用於治療阿茲海默症或亨丁頓氏症之用途
WO2020242933A1 (en) * 2019-05-24 2020-12-03 Emory University Asparagine endopeptidase (aep) inhibitors, compositions, and uses related thereto
AU2020312647A1 (en) * 2019-07-12 2022-02-24 Scenic Immunology B.V. N-substituted-3,4-(fused 5-ring)-5-phenyl-pyrrolidine-2-one compounds as inhibitors of isoQC and/or QC enzyme
KR20240024948A (ko) 2021-06-24 2024-02-26 인실리코 메디신 아이피 리미티드 질환의 치료를 위한 베타-락탐 유도체
WO2025021012A1 (en) * 2023-07-21 2025-01-30 Insilico Medicine Ip Limited Crystalline beta-lactam derivatives and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD293584A5 (de) * 1990-03-23 1991-09-05 Adw,Zi Fuer Organische Chemie,De Verfahren zur herstellung von neuen 3,5,5-trisubstituierten 1-(benzimidazol-2-yl)-imidazolidin-2,4-dionen bzw. -4-on-2-thionen
DE4320432A1 (de) 1993-06-21 1994-12-22 Bayer Ag Substituierte Mono- und Bipyridylmethylderivate
US20040006011A1 (en) * 1996-07-12 2004-01-08 Gour Barbara J. Peptidomimetic modulators of cell adhesion
NZ501166A (en) 1997-07-31 2001-12-21 Abbott Lab Reverse hydroxamate-containing compounds and their use as inhibitors of matrix metalloproteinases
US6235786B1 (en) 1997-08-06 2001-05-22 Abbott Laboratories Reverse hydroxamate inhibitors of matrix metalloproteinases
ZA200508439B (en) * 2003-05-05 2007-03-28 Probiodrug Ag Medical use of inhibitors of glutaminyl and glutamate cyclases
CA2554809C (en) 2004-02-05 2014-04-29 Probiodrug Ag Novel n-alkyl thiourea- and thioamide-substituted imidazolyl inhibitors of glutaminyl cyclase
WO2008028032A2 (en) 2006-09-01 2008-03-06 Allergan, Inc. Therapeutic substituted hydantoins and related compounds
EP2082041B1 (en) * 2006-09-21 2018-03-14 Probiodrug AG Novel genes related to glutaminyl cyclase
EP2091945B1 (en) * 2006-11-09 2014-01-15 Probiodrug AG Novel inhibitors of glutaminyl cyclase
TW200831080A (en) 2006-12-15 2008-08-01 Irm Llc Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
CN101519376B (zh) 2008-02-27 2012-10-10 上海药明康德新药开发有限公司 一种芳香环双酰胺螺环类药物模板的合成方法
EP2344158B1 (en) 2008-09-04 2017-12-27 Probiodrug AG Use of isoqc inhibitors

Also Published As

Publication number Publication date
CA2735795A1 (en) 2010-03-11
IL211018A0 (en) 2011-04-28
NZ591531A (en) 2012-03-30
ES2599621T3 (es) 2017-02-02
US8962860B2 (en) 2015-02-24
ZA201100898B (en) 2012-02-29
EA021150B1 (ru) 2015-04-30
KR20110074975A (ko) 2011-07-05
DK2344157T3 (en) 2016-09-05
MX2011002106A (es) 2011-04-07
KR101694556B1 (ko) 2017-01-09
JP5707327B2 (ja) 2015-04-30
AU2009289238B2 (en) 2014-09-04
AU2009289238A1 (en) 2010-03-11
CN102186475A (zh) 2011-09-14
CN102186475B (zh) 2016-08-03
CA2735795C (en) 2018-02-20
WO2010026212A1 (en) 2010-03-11
US20100119475A1 (en) 2010-05-13
EA201100424A1 (ru) 2011-10-31
SG193828A1 (en) 2013-10-30
EP2344157B1 (en) 2016-05-25
BRPI0918564B1 (pt) 2023-11-28
IL211018A (en) 2015-11-30
EP2344157A1 (en) 2011-07-20
JP2012502006A (ja) 2012-01-26

Similar Documents

Publication Publication Date Title
CY2020023I1 (el) Αναστολεiς βητα-λακταμασων
FIC20240020I1 (fi) Atetsolitsumabi
FIC20210049I1 (fi) Satralitsumabi
CY2017016I1 (el) Αναστολεις πρωτεασωματος
EP2305306A4 (en) NEURO INVASION INHIBITOR
BRPI0918564A2 (pt) inibidores
DE602009000234D1 (de) msignals
DK3444343T3 (da) Polypeptider
EP2320913A4 (en) NUCLEIC ACID APTAMERS
FI8206U1 (fi) Kanylointisimulantti
NL300884I2 (nl) Ozenoxacin
EP2377648A4 (en) GRINDING MACHINE INNER TOOTH WHEEL
EP2318641A4 (en) TOOL FOR CENTERING FOR DRILLING ENCLOSURE
EP2360457A4 (en) Gas shutoff device
DK2240506T3 (da) IAP inhibitorer
DK2331548T3 (da) Proteasehæmmere
ES1067763Y (es) Dendrometro
FI20075320A0 (fi) Uusia käyttökelpoisia inhibiittoreita
FI8195U1 (fi) Suunhoitovalmiste
ES1068094Y (es) Horno-barbacoa
ITPD20080028A1 (it) Fisioscissore
FI8423U1 (fi) Nuotioalusta
FI8318U1 (fi) Liukukiskosovitelma
FIU20080262U0 (fi) Paalauslaite
FI20085422A0 (fi) Perunanistutuskone

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B25D Requested change of name of applicant approved

Owner name: VIVORYON THERAPEUTICS AG (DE)

B25D Requested change of name of applicant approved

Owner name: VIVORYON THERAPEUTICS N.V. (DE)

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 04/09/2009, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.